Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Bioceres Crop Solutions (BIOX) over the last 10 years, with Q3 2025 value amounting to $15.5 million.

  • Bioceres Crop Solutions' Cash & Equivalents fell 6513.6% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year decrease of 6513.6%. This contributed to the annual value of $44.5 million for FY2025, which is 0.0% changed from last year.
  • As of Q3 2025, Bioceres Crop Solutions' Cash & Equivalents stood at $15.5 million, which was down 6513.6% from $44.5 million recorded in Q2 2025.
  • In the past 5 years, Bioceres Crop Solutions' Cash & Equivalents ranged from a high of $57.7 million in Q1 2023 and a low of -$68.6 million during Q4 2022
  • For the 5-year period, Bioceres Crop Solutions' Cash & Equivalents averaged around $24.8 million, with its median value being $38.5 million (2025).
  • In the last 5 years, Bioceres Crop Solutions' Cash & Equivalents plummeted by 28863.71% in 2022 and then surged by 33449.38% in 2025.
  • Bioceres Crop Solutions' Cash & Equivalents (Quarter) stood at $36.4 million in 2021, then crashed by 288.64% to -$68.6 million in 2022, then surged by 64.43% to -$24.4 million in 2023, then surged by 282.27% to $44.5 million in 2024, then plummeted by 65.14% to $15.5 million in 2025.
  • Its Cash & Equivalents stands at $15.5 million for Q3 2025, versus $44.5 million for Q2 2025 and $38.5 million for Q1 2025.